STAT5B and neoplasm: Kollman et al. discovered that somatic mutations in STAT5b, such as the SH2 domain mutation of STAT5b N642H, inhibited interferon-α/γ (IFNα/γ) signalling in Bcr-Abl-driven leukaemia, thus promoting tumour formation and growth [81,98].